🇮🇹 Hu38Sb19 in Italy

AIFA authorised Hu38Sb19 on 30 May 2020

Marketing authorisation

AIFA — authorised 30 May 2020

  • Marketing authorisation holder: Sanofi-Aventis groupe
  • Status: approved

Hu38Sb19 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Italy

Frequently asked questions

Is Hu38Sb19 approved in Italy?

Yes. AIFA authorised it on 30 May 2020.

Who is the marketing authorisation holder for Hu38Sb19 in Italy?

Sanofi-Aventis groupe holds the Italian marketing authorisation.